SomnoMed (ASX:SOM) said it will absorb the immediate costs from new US tariffs in the immediate term, according to a Monday filing with the Australian bourse.
The company, which manufactures its products in the Philippines, is assessing the evolving impact of the tariffs, the filing said.
SomnoMed reaffirmed its fiscal year revenue guidance of about AU$105 million, with earnings before interest, taxes, depreciation, and amortization expected in the range of AU$7 million to AU$9 million, the filing added.
Shares of the company fell 19% at market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.